Surgical resection is the only curative option for pancreatic cancer. Dr. Vinod T. Gore performs Robotic Whipple's (Pancreaticoduodenectomy), Robotic Distal Pancreatectomy (RAMPS), and complex vascular reconstructions — with 300+ robotic procedures and FARIS certification from the University of Edinburgh.
The pancreas is a gland behind the stomach with two functions: producing digestive enzymes (exocrine) and hormones like insulin (endocrine). Pancreatic cancer arises from the ductal epithelium in 85–90% of cases (Pancreatic Ductal Adenocarcinoma — PDAC) and is notoriously difficult to detect early.
60–70% of tumours arise in the head of the pancreas — where they obstruct the bile duct, causing painless jaundice. Body and tail tumours cause vague back pain and weight loss, and are often diagnosed at a later stage as they cause no jaundice.
Despite its challenging reputation, surgical resection with adjuvant chemotherapy (FOLFIRINOX) offers genuine long-term survival and cure in fit patients with resectable disease. The key is expert evaluation — many patients told their cancer is inoperable elsewhere have been successfully resected at specialist centres.
The most important staging question in pancreatic cancer is the relationship of the tumour to the major blood vessels (superior mesenteric artery, coeliac axis, portal vein, and superior mesenteric vein). CT with pancreatic protocol (triphasic) + PET-CT + EUS provides this information.
Every pancreatic cancer case follows an MDT-guided pathway. The sequence of chemotherapy and surgery depends on the resectability category — with neoadjuvant FOLFIRINOX now standard for borderline resectable disease.
After removing the head of the pancreas, duodenum, bile duct, and gallbladder — the digestive tract must be reconstructed with three separate joins. The precision and technique of each anastomosis determines the complication rate. This is where the robotic platform's advantages are most meaningful.
The surgical approach depends on the location of the tumour within the pancreas. Head and neck tumours require Whipple's. Body and tail tumours require distal pancreatectomy (RAMPS). Diffuse tumours occasionally require total pancreatectomy.
Whipple's procedure (pancreaticoduodenectomy) removes the head of the pancreas, the entire duodenum, the distal bile duct, the gallbladder, and in classic Whipple the distal stomach. Dr. Gore performs the pylorus-preserving variant (PPPD) as standard — retaining the stomach and pylorus to reduce post-operative nutritional complications. The robotic platform provides decisive advantages in this extraordinarily complex operation.
For borderline resectable tumours with portal vein or SMV involvement — vascular resection and reconstruction extends the possibility of complete R0 resection to patients who would otherwise be considered inoperable. This is the frontier of pancreatic cancer surgery.
Whipple's procedure has a complication rate of 40–60% at most centres — though the majority are minor. Major complications are managed at the bedside or with radiological intervention. Mortality at specialist high-volume centres is now under 3%.
Whipple's procedure (pancreaticoduodenectomy) removes the head of the pancreas, entire duodenum, distal bile duct, and gallbladder. It is performed for cancers of the head of the pancreas, ampullary cancer, distal bile duct cancer, and duodenal cancer. It is one of the most complex abdominal operations in surgery — requiring an experienced surgeon at a high-volume centre. Dr. Gore performs the pylorus-preserving variant (PPPD) as standard, along with robotic-assisted technique for eligible patients.
Robotic Whipple's has been shown in multiple international studies to be safe and to offer specific advantages over open surgery — particularly in terms of blood loss, hospital stay, and the precision of the pancreaticojejunostomy anastomosis (reducing post-operative pancreatic fistula rates). The oncological outcomes — R0 resection margins, lymph node yield, and long-term survival — are equivalent to open surgery. Dr. Gore has performed 300+ robotic procedures and holds the FARIS certification from the University of Edinburgh.
Distal pancreatectomy removes the body and tail of the pancreas — used for cancers of the pancreatic body and tail. Whipple's removes the head of the pancreas. They are completely different operations for tumours in different parts of the gland. For cancer, Dr. Gore performs RAMPS (Radical Antegrade Modular Pancreatosplenectomy) — achieving better posterior resection margins by dissecting anterior to the left adrenal gland.
POPF is a leakage of pancreatic juice from the pancreatic anastomosis after Whipple's or from the staple line after distal pancreatectomy. It occurs in 15–30% of cases and is the most common serious complication of pancreatic surgery. Grade B (requiring intervention) is managed with prolonged drain, octreotide, and antibiotics. Grade C (causing haemorrhage or sepsis) may require reoperation. Robotic Whipple's reduces POPF rates through more precise duct-to-mucosa pancreaticojejunostomy.
Borderline resectable pancreatic cancer means the tumour contacts but does not fully encase the major blood vessels — <180 degrees of vessel involvement. These tumours cannot safely be removed upfront, but may become resectable after neoadjuvant FOLFIRINOX chemotherapy (4–6 cycles). After neoadjuvant therapy, restaging CT determines whether surgery is now feasible. Vascular resection and reconstruction may still be required at surgery.
For resectable disease after surgery: modified FOLFIRINOX (5-FU, leucovorin, irinotecan, oxaliplatin) or Gemcitabine + Capecitabine are the two standard adjuvant regimens. For borderline resectable or locally advanced disease: FOLFIRINOX (4–6 cycles) or Gemcitabine + nab-Paclitaxel (Abraxane) as neoadjuvant therapy. For metastatic disease: FOLFIRINOX or Gem+nab-Paclitaxel as palliative first-line.
After robotic Whipple's: ICU or HDU overnight, hospital 9–12 days. A drain is left near the pancreatic anastomosis — removed when drain fluid amylase is low. Diet progresses from clear fluids to soft food over 7–10 days. Pancreatic enzyme replacement (Creon) is prescribed to aid digestion. Full recovery takes 8–12 weeks. Adjuvant chemotherapy begins 6–8 weeks post-operatively. Open Whipple's: hospital 10–14 days, recovery 10–14 weeks.
Bring your CT (pancreatic protocol), PET-CT, MRCP, EUS report, and CA 19-9. Dr. Gore will independently review all imaging and give an honest assessment of resectability — including vascular involvement and whether neoadjuvant FOLFIRINOX is appropriate.